The characteristics of COVID-19 vaccine-related headache: Clues gathered from the healthcare personnel in the pandemic

dc.contributor.authorEkizoglu, Esme
dc.contributor.authorGezegen, Hasim
dc.contributor.authorYalinay Dikmen, Pinar
dc.contributor.authorOrhan, Elif Kocasoy
dc.contributor.authorErtas, Mustafa
dc.contributor.authorBaykan, Betul
dc.date.accessioned2023-02-21T12:32:54Z
dc.date.available2023-02-21T12:32:54Z
dc.date.issued2022-01-01
dc.description.abstractIntroduction Headache is a frequent adverse event after viral vaccines. We aimed to investigate the frequency and clinical associations of COVID-19 vaccine-related headache. Methods The characteristics, associations of this headache, main comorbidities, headache history following the influenza vaccine and during COVID-19 were investigated using a web-based questionnaire. Results A total of 1819 healthcare personnel (mean age: 44.4 +/- 13.4 years, 1222 females), vaccinated with inactivated virus, contributed to the survey
dc.description.abstract209 (11.4\%) had been infected with COVID-19. A total of 556 participants (30.6\%) reported headache with significant female dominance (36.1\% vs. 19.3\%), 1.8 +/- 3.5 (median: 1
dc.description.abstractIQR: 0-2) days following vaccination. One hundred and forty-four participants (25.9\%) experienced headache lasting >= 3 days. Headache was mostly bilateral without accompanying phenomena, less severe, and shorter than COVID-19-related headache. The presence of primary headaches and migraine were significantly associated with COVID-19 vaccine-related headache (ORs = 2.16 {[}95\% CI 1.74-2.68] and 1.65 {[}1.24-2.19], respectively). Headache during COVID-19 or following influenza vaccine also showed significant association with headache following COVID-19 vaccine (OR = 4.3 {[}95\% CI 1.82-10.2] and OR = 4.84 {[}95\% CI 2.84-8.23], respectively). Only thyroid diseases showed a significant association (OR = 1.54 {[}95\% CI 1.15-2.08]) with vaccine-related headache among the common comorbidities. Conclusion Headache is observed in 30.6\% of the healthcare workers following COVID-19 vaccine and mostly experienced by females with pre-existing primary headaches, thyroid disorders, headache during COVID-19, or headache related to the influenza vaccine.
dc.description.issue4-5
dc.description.issueAPR
dc.description.pages366-375
dc.description.volume42
dc.identifier.doi10.1177/03331024211042390
dc.identifier.urihttps://hdl.handle.net/11443/1312
dc.identifier.urihttp://dx.doi.org/10.1177/03331024211042390
dc.identifier.wosWOS:000695334200001
dc.publisherSAGE PUBLICATIONS LTD
dc.relation.ispartofCEPHALALGIA
dc.subjectCOVID-19 vaccine
dc.subjectvaccination
dc.subjectvaccine
dc.subjectheadache
dc.subjectadverse event
dc.titleThe characteristics of COVID-19 vaccine-related headache: Clues gathered from the healthcare personnel in the pandemic
dc.typeArticle
Dosyalar
Orijinal seri
Şimdi gösteriliyor 1 - 1 / 1
thumbnail.default.alt
Ad:
03331024211042390.pdf
Boyut:
339.74 KB
Format:
Adobe Portable Document Format
Açıklama
Koleksiyonlar